Models for 10,000 Human Diseases

In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for safety and efficacy. Here, we dive into a recent study that identified novel potential mediators of liver fibrosis using a genome-wide CRISPR screen in primary human liver cells. Studies like this are a starting point towards understanding the mechanisms underlying liver fibrosis and will hopefully help to reveal new drug targets for NASH and other forms of liver fibrosis.  What causes liver fibrosis? What we know so far...  Liver...